296 related articles for article (PubMed ID: 16904708)
1. The acrylamide (S)-1 differentially affects Kv7 (KCNQ) potassium channels.
Bentzen BH; Schmitt N; Calloe K; Dalby Brown W; Grunnet M; Olesen SP
Neuropharmacology; 2006 Nov; 51(6):1068-77. PubMed ID: 16904708
[TBL] [Abstract][Full Text] [Related]
2. The acrylamide (S)-2 as a positive and negative modulator of Kv7 channels expressed in Xenopus laevis oocytes.
Blom SM; Schmitt N; Jensen HS
PLoS One; 2009 Dec; 4(12):e8251. PubMed ID: 20011514
[TBL] [Abstract][Full Text] [Related]
3. Synthesis and structure-activity relationship of acrylamides as KCNQ2 potassium channel openers.
Wu YJ; He H; Sun LQ; L'Heureux A; Chen J; Dextraze P; Starrett JE; Boissard CG; Gribkoff VK; Natale J; Dworetzky SI
J Med Chem; 2004 May; 47(11):2887-96. PubMed ID: 15139767
[TBL] [Abstract][Full Text] [Related]
4. Anxiolytic effects of Maxipost (BMS-204352) and retigabine via activation of neuronal Kv7 channels.
Korsgaard MP; Hartz BP; Brown WD; Ahring PK; Strøbaek D; Mirza NR
J Pharmacol Exp Ther; 2005 Jul; 314(1):282-92. PubMed ID: 15814569
[TBL] [Abstract][Full Text] [Related]
5. The KCNQ5 potassium channel from mouse: a broadly expressed M-current like potassium channel modulated by zinc, pH, and volume changes.
Jensen HS; Callø K; Jespersen T; Jensen BS; Olesen SP
Brain Res Mol Brain Res; 2005 Sep; 139(1):52-62. PubMed ID: 15963599
[TBL] [Abstract][Full Text] [Related]
6. N-(6-chloro-pyridin-3-yl)-3,4-difluoro-benzamide (ICA-27243): a novel, selective KCNQ2/Q3 potassium channel activator.
Wickenden AD; Krajewski JL; London B; Wagoner PK; Wilson WA; Clark S; Roeloffs R; McNaughton-Smith G; Rigdon GC
Mol Pharmacol; 2008 Mar; 73(3):977-86. PubMed ID: 18089837
[TBL] [Abstract][Full Text] [Related]
7. Molecular determinants of KCNQ1 channel block by a benzodiazepine.
Seebohm G; Chen J; Strutz N; Culberson C; Lerche C; Sanguinetti MC
Mol Pharmacol; 2003 Jul; 64(1):70-7. PubMed ID: 12815162
[TBL] [Abstract][Full Text] [Related]
8. Molecular determinants of KCNQ (Kv7) K+ channel sensitivity to the anticonvulsant retigabine.
Schenzer A; Friedrich T; Pusch M; Saftig P; Jentsch TJ; Grötzinger J; Schwake M
J Neurosci; 2005 May; 25(20):5051-60. PubMed ID: 15901787
[TBL] [Abstract][Full Text] [Related]
9. The KCNQ2/3 selective channel opener ICA-27243 binds to a novel voltage-sensor domain site.
Padilla K; Wickenden AD; Gerlach AC; McCormack K
Neurosci Lett; 2009 Nov; 465(2):138-42. PubMed ID: 19733209
[TBL] [Abstract][Full Text] [Related]
10. Studies of the effect of ionomycin on the KCNQ4 channel expressed in Xenopus oocytes.
Su CC; Li SY; Yang JJ; Su MC; Lin MJ
Biochem Biophys Res Commun; 2006 Sep; 348(1):295-300. PubMed ID: 16876114
[TBL] [Abstract][Full Text] [Related]
11. Molecular pharmacology and therapeutic potential of neuronal Kv7-modulating drugs.
Miceli F; Soldovieri MV; Martire M; Taglialatela M
Curr Opin Pharmacol; 2008 Feb; 8(1):65-74. PubMed ID: 18061539
[TBL] [Abstract][Full Text] [Related]
12. Electrophysiological and pharmacological characterization of a novel and potent neuronal Kv7 channel opener SCR2682 for antiepilepsy.
Zhang F; Liu Y; Tang F; Liang B; Chen H; Zhang H; Wang K
FASEB J; 2019 Aug; 33(8):9154-9166. PubMed ID: 31063701
[TBL] [Abstract][Full Text] [Related]
13. (S)-N-[1-(4-cyclopropylmethyl-3,4-dihydro-2H-benzo[1,4]oxazin-6-yl)-ethyl]-3-(2-fluoro-phenyl)-acrylamide is a potent and efficacious KCNQ2 opener which inhibits induced hyperexcitability of rat hippocampal neurons.
Wu YJ; Boissard CG; Chen J; Fitzpatrick W; Gao Q; Gribkoff VK; Harden DG; He H; Knox RJ; Natale J; Pieschl RL; Starrett JE; Sun LQ; Thompson M; Weaver D; Wu D; Dworetzky SI
Bioorg Med Chem Lett; 2004 Apr; 14(8):1991-5. PubMed ID: 15050644
[TBL] [Abstract][Full Text] [Related]
14. XE991 and Linopirdine Are State-Dependent Inhibitors for Kv7/KCNQ Channels that Favor Activated Single Subunits.
Greene DL; Kang S; Hoshi N
J Pharmacol Exp Ther; 2017 Jul; 362(1):177-185. PubMed ID: 28483800
[TBL] [Abstract][Full Text] [Related]
15. The new anticonvulsant retigabine favors voltage-dependent opening of the Kv7.2 (KCNQ2) channel by binding to its activation gate.
Wuttke TV; Seebohm G; Bail S; Maljevic S; Lerche H
Mol Pharmacol; 2005 Apr; 67(4):1009-17. PubMed ID: 15662042
[TBL] [Abstract][Full Text] [Related]
16. Amitriptyline is a potent blocker of human Kv1.1 and Kv7.2/7.3 channels.
Punke MA; Friederich P
Anesth Analg; 2007 May; 104(5):1256-64, tables of contents. PubMed ID: 17456683
[TBL] [Abstract][Full Text] [Related]
17. Activation of Kv7 (KCNQ) voltage-gated potassium channels by synthetic compounds.
Xiong Q; Gao Z; Wang W; Li M
Trends Pharmacol Sci; 2008 Feb; 29(2):99-107. PubMed ID: 18206251
[TBL] [Abstract][Full Text] [Related]
18. Functional and behavioral signatures of Kv7 activator drug subtypes.
Kanyo R; Wang CK; Locskai LF; Li J; Allison WT; Kurata HT
Epilepsia; 2020 Aug; 61(8):1678-1690. PubMed ID: 32652600
[TBL] [Abstract][Full Text] [Related]
19. (S)-N-[1-(3-morpholin-4-ylphenyl)ethyl]- 3-phenylacrylamide: an orally bioavailable KCNQ2 opener with significant activity in a cortical spreading depression model of migraine.
Wu YJ; Boissard CG; Greco C; Gribkoff VK; Harden DG; He H; L'Heureux A; Kang SH; Kinney GG; Knox RJ; Natale J; Newton AE; Lehtinen-Oboma S; Sinz MW; Sivarao DV; Starrett JE; Sun LQ; Tertyshnikova S; Thompson MW; Weaver D; Wong HS; Zhang L; Dworetzky SI
J Med Chem; 2003 Jul; 46(15):3197-200. PubMed ID: 12852750
[TBL] [Abstract][Full Text] [Related]
20. Atomic basis for therapeutic activation of neuronal potassium channels.
Kim RY; Yau MC; Galpin JD; Seebohm G; Ahern CA; Pless SA; Kurata HT
Nat Commun; 2015 Sep; 6():8116. PubMed ID: 26333338
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
